Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

Share Options

31 Aug 2011 14:44

RNS Number : 3548N
Angle PLC
31 August 2011
 



For immediate release

31 August 2011

 

ANGLE plc ("the Company")

 

Share Options

 

Reflecting the current developments within the business and the need to ensure ongoing incentivisation of the management team, the Remuneration Committee has cancelled certain existing share options over ordinary shares in the Company issued to staff and directors and issued new share options at the current market price.

 

Following the cancellation of 940,422 existing share options and the issue of 1,856,000 new share options, the Company now has outstanding options issued to staff and directors over a total of 2,055,397 ordinary shares being 5.8% of the shares currently in issue.

 

The exercise price for the new share options is set at the current mid market price of 25.75 pence per share. Vesting of the share options will be subject to a performance condition that the share price together with any dividend payments has risen by at least 50% from the current market price. The share options will vest over a three year period and expire ten years after issue.

 

Following the new issue of share options, the total number of share options held by the directors and senior management of the Company are:

 

Options (% issued)

Before issue

After issue

Increase

Andrew Newland, Chief Executive

648,675 (1.8%)

950,000 (2.7%)

301,325 (0.8%)

Ian Griffiths, Finance Director

247,619 (0.7%)

500,000 (1.4%)

252,381 (0.7%)

Shane Booth, Parsortix CEO

33,810 (0.1%)

250,000 (0.7%)

216,190 (0.6%)

 

 

The non-executive directors do not hold share options.

 

ANGLE Chairman, Garth Selvey, commented:

"The new options are part of a revitalised remuneration scheme which takes account of changes within the Company and replace four sets of options awarded between 2005 and 2007. The new options also take into account salary waived by senior members of the Company."

 

 

For further information:

ANGLE plc

01483 685830

Garth Selvey, Chairman

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

Collins Stewart Europe Limited

Matt Goode

0207 523 8350

Buchanan

Lisa Baderoon, Catherine Breen

020 7466 5000

Scott Harris

Stephen Scott, James O'Shaughnessy, Harry Dee

0207 653 0030

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCDKDDQNBKDNFN
Date   Source Headline
3rd Jun 20157:00 amRNSAppointment of Scientific Adviser
26th May 20157:01 amRNSNew Patent Grants
21st Apr 20157:00 amRNSOvarian Cancer Update
20th Apr 20157:00 amRNSSidney Kimmel Cancer Centre
14th Apr 20157:00 amRNSIssue of Equity
4th Mar 20157:00 amRNSOffer to Shareholders
25th Feb 20151:11 pmRNSIssue of Equity
20th Feb 20154:05 pmRNSHolding(s) in Company
16th Feb 20157:01 amRNSMD Anderson Collaboration
16th Feb 20157:00 amRNSPlacing, Subscription and Offer
29th Jan 20157:00 amRNSInterim Results
27th Jan 20157:01 amRNS"Unprecedented Specificity" in Ovarian Cancer
23rd Jan 20157:00 amRNSCorporate Collaboration
23rd Jan 20157:00 amRNSPointMan collaboration with ANGLE plc
21st Jan 20153:00 pmRNSFurther information re Director's share transfer
19th Jan 20157:00 amRNSNotification of Interim Results
8th Jan 20157:00 amRNSCorporate Collaboration
15th Dec 20147:00 amRNSCancer Research Manchester Institute Publication
12th Nov 20147:00 amRNSFurther information re Director's share transfer
10th Nov 20147:00 amRNSIssue of Share Options
31st Oct 20147:00 amRNSADR PROGRAMME
21st Oct 20147:00 amRNSDirector's Share Transfer
17th Oct 20147:00 amRNSKey Opinion Leaders Report on Parsortix System
17th Oct 20147:00 amRNSCollaboration with Barts Cancer Institute
30th Sep 20144:30 pmRNSResult of AGM
30th Sep 20147:00 amRNSCollaboration with Thomas Jefferson University
25th Sep 20147:00 amRNSADR Programme, FDA Update and US Appointment
19th Sep 20147:00 amRNSBreast Cancer Collaboration
17th Sep 20147:00 amRNSCollaboration with Medical University of Vienna
8th Sep 20147:00 amRNSHamburg-Eppendorf Collaboration
4th Aug 20147:00 amRNSParsortix Granted Second US Patent
23rd Jul 20147:00 amRNSPreliminary Results
22nd Jul 20147:00 amRNSParsortix Evaluation
1st Jul 20147:00 amRNSNotification of Preliminary Results
29th Apr 20144:30 pmRNSHoldings in Company
8th Apr 20147:00 amRNSIntellectual Property Update
24th Mar 20147:00 amRNSAppointment of Scientific Adviser
17th Mar 20147:00 amRNSParsortix FDA Submission
24th Feb 20147:00 amRNSUse of Parsortix System with Liver Cancer Patients
18th Feb 20147:00 amRNSParsortix Launch at Circulate Conference in Berlin
30th Jan 20147:00 amRNSInterim Results
13th Jan 20147:00 amRNSCambridge Parsortix Laboratory
10th Jan 20147:00 amRNSNotification of Interim Results and Webcast
7th Jan 20147:00 amRNSAppointment of Scientific Adviser
17th Dec 20137:00 amRNSCE Mark Authorisation
13th Dec 20137:00 amRNSRaises £6.2m from Sale of Geomerics
31st Oct 20133:31 pmRNSResult of 2013 Annual General Meeting
9th Oct 20137:00 amRNSAnnual Report and Accounts and Notice of AGM
31st Jul 20137:00 amRNSPreliminary Results
25th Jul 20137:00 amRNSPositive Evaluation of Parsortix System

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.